BR0116005A - Compostos de bisarila nìtricos, orto-substituìdos, para uso como inibidores de canal de potássio - Google Patents

Compostos de bisarila nìtricos, orto-substituìdos, para uso como inibidores de canal de potássio

Info

Publication number
BR0116005A
BR0116005A BR0116005-2A BR0116005A BR0116005A BR 0116005 A BR0116005 A BR 0116005A BR 0116005 A BR0116005 A BR 0116005A BR 0116005 A BR0116005 A BR 0116005A
Authority
BR
Brazil
Prior art keywords
potassium channel
ortho
channel inhibitors
compounds
substituted
Prior art date
Application number
BR0116005-2A
Other languages
English (en)
Inventor
Stefan Peukert
Joachim Brendel
Horst Hemmerle
Heinz-Werner Kleemann
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0116005A publication Critical patent/BR0116005A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTOS DE BISARILA NìTRICOS, ORTO-SUBSTITUìDOS, PARA USO COMO INIBIDORES DE CANAL DE POTáSSIO". Compostos da fórmula I, na qual A1 a A8, R(1), R(2), R(3), R(4), R(30) e R(31) têm os significados indicados nas reivindicações, são particularmente apropriados para uso como substâncias ativas anti-arrítmicas, especialmente para tratamento e profilaxia de arritmias atriais, por exemplo, fibrilação atrial (AF) ou palpitação atrial.
BR0116005-2A 2000-12-07 2001-11-24 Compostos de bisarila nìtricos, orto-substituìdos, para uso como inibidores de canal de potássio BR0116005A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10060807A DE10060807A1 (de) 2000-12-07 2000-12-07 Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
PCT/EP2001/013680 WO2002046162A1 (de) 2000-12-07 2001-11-24 Ortho-substituierte stickstoffhaltige bisarylverbindungen zur verwendung als kalium-kanal-inhibitoren

Publications (1)

Publication Number Publication Date
BR0116005A true BR0116005A (pt) 2004-01-06

Family

ID=7666129

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116005-2A BR0116005A (pt) 2000-12-07 2001-11-24 Compostos de bisarila nìtricos, orto-substituìdos, para uso como inibidores de canal de potássio

Country Status (31)

Country Link
US (1) US6794377B2 (pt)
EP (1) EP1341764B1 (pt)
JP (1) JP4445198B2 (pt)
KR (1) KR100815070B1 (pt)
CN (1) CN1237052C (pt)
AR (1) AR033408A1 (pt)
AT (1) ATE297897T1 (pt)
AU (2) AU2002221892B2 (pt)
BR (1) BR0116005A (pt)
CA (1) CA2436891C (pt)
CZ (1) CZ301923B6 (pt)
DE (2) DE10060807A1 (pt)
DK (1) DK1341764T3 (pt)
EE (1) EE05220B1 (pt)
ES (1) ES2242792T3 (pt)
HK (1) HK1066539A1 (pt)
HR (1) HRP20030448B1 (pt)
HU (1) HUP0302762A3 (pt)
IL (2) IL156312A0 (pt)
MX (1) MXPA03004966A (pt)
NO (1) NO325297B1 (pt)
NZ (1) NZ526294A (pt)
PL (1) PL207057B1 (pt)
PT (1) PT1341764E (pt)
RU (1) RU2275360C2 (pt)
SI (1) SI1341764T1 (pt)
SK (1) SK286056B6 (pt)
TW (1) TWI242005B (pt)
WO (1) WO2002046162A1 (pt)
YU (1) YU40203A (pt)
ZA (1) ZA200303931B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
DK1474395T3 (da) * 2002-02-12 2008-02-11 Smithkline Beecham Corp Nicotinamidderivater, der er nyttige som p38-inhibitorer
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
US20050054673A1 (en) * 2003-09-08 2005-03-10 Aventis Pharma Deutschland Gmbh Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
JP2008522978A (ja) * 2004-12-07 2008-07-03 エナンタ ファーマシューティカルズ インコーポレイテッド ３，６−ビシクロライド
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
CA2615440A1 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
JP5161871B2 (ja) * 2006-04-27 2013-03-13 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｔａｓｋ−１およびｔａｓｋ−３イオンチャンネルの阻害剤
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
JP5485391B2 (ja) 2009-07-30 2014-05-07 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ７調節薬としてのジヒドロピリミドンアミド類
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (pt) 2011-07-01 2018-04-28
US20150045305A1 (en) 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
EP3263559A1 (en) * 2013-01-22 2018-01-03 Technische Universität Graz Lipase inhibitors
WO2014183221A1 (en) * 2013-05-17 2014-11-20 The Centre For Drug Research And Development Resveratrol analogs and therapeutic uses thereof
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
EP3558992A4 (en) * 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. ACTIVATOR OF TREK (TWIK-ASSOCIATED K + CHANNELS) CHANNELS
HRP20220331T1 (hr) 2018-03-08 2022-05-13 Incyte Corporation Spojevi aminopirazin diola kao inhibitori pi3k-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4616002A (en) * 1984-11-09 1986-10-07 Ciba-Geigy Corporation Dihydro pyridine compounds, compositions and use
US5196537A (en) * 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
DE4430638A1 (de) * 1994-08-29 1996-03-07 Bayer Ag Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
CA2334258A1 (en) 1998-06-05 1999-12-09 Icagen, Inc. Potassium channel inhibitors
CA2341678C (en) * 1998-09-01 2009-10-13 Bristol-Myers Squibb Company Potassium channel inhibitors and method
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
HK1066539A1 (en) 2005-03-24
CA2436891C (en) 2011-01-11
CA2436891A1 (en) 2002-06-13
EP1341764B1 (de) 2005-06-15
CZ20031564A3 (cs) 2003-09-17
DE50106549D1 (de) 2005-07-21
CN1237052C (zh) 2006-01-18
MXPA03004966A (es) 2003-09-25
US6794377B2 (en) 2004-09-21
HRP20030448A2 (en) 2005-04-30
AR033408A1 (es) 2003-12-17
HRP20030448B1 (en) 2006-06-30
US20030060470A1 (en) 2003-03-27
ZA200303931B (en) 2004-03-24
PT1341764E (pt) 2005-09-30
HUP0302762A2 (hu) 2003-11-28
YU40203A (sh) 2006-05-25
ATE297897T1 (de) 2005-07-15
NO20032488L (no) 2003-08-04
NO325297B1 (no) 2008-03-17
AU2189202A (en) 2002-06-18
IL156312A (en) 2009-05-04
ES2242792T3 (es) 2005-11-16
DK1341764T3 (da) 2005-10-17
PL365318A1 (en) 2004-12-27
KR100815070B1 (ko) 2008-03-20
JP4445198B2 (ja) 2010-04-07
NO20032488D0 (no) 2003-06-02
AU2002221892B2 (en) 2006-07-13
JP2004515493A (ja) 2004-05-27
EE05220B1 (et) 2009-10-15
HUP0302762A3 (en) 2010-03-29
SK6872003A3 (en) 2004-02-03
CZ301923B6 (cs) 2010-07-28
KR20030081344A (ko) 2003-10-17
CN1537102A (zh) 2004-10-13
TWI242005B (en) 2005-10-21
NZ526294A (en) 2005-04-29
IL156312A0 (en) 2004-01-04
DE10060807A1 (de) 2002-06-20
SK286056B6 (sk) 2008-02-05
RU2275360C2 (ru) 2006-04-27
EP1341764A1 (de) 2003-09-10
PL207057B1 (pl) 2010-10-29
SI1341764T1 (en) 2005-10-31
EE200300225A (et) 2003-08-15
WO2002046162A1 (de) 2002-06-13

Similar Documents

Publication Publication Date Title
BR0116005A (pt) Compostos de bisarila nìtricos, orto-substituìdos, para uso como inibidores de canal de potássio
BR0116084A (pt) Amidas de ácido furanocarboxìlico e tiofenocarboxìlico ariladas com efeito bloqueador de canal de potássio
BR0200782A (pt) Compostos para o tratamento da isquemia
CL2004001129A1 (es) Compuestos derivados de halogenopirimidinas aril tio-eter; composicion pesticida; procedimiento de preparacion; compuestos intermediarios; y uso del compuesto como agente pesticida.
BR9916192A (pt) Formulações agroquìmicas
RS37603A (en) Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, theis urse as a medicament and pharmaceutical preparations containing these compounds
BR0014465A (pt) 1,1'-bifenil-2-carbonamidas 2'-substituìdas, processos para a sua preparação,seu emprego como medicamento bem como os preparados farmacêuticos contendo as mesmas
ES2169654B1 (es) Agente desfoliante
TR200103701T2 (tr) İndanil ikameli benzolkarbonamidleri, imalat yöntemleri, ilaç olarak kullanımları
NO20003600D0 (no) Kaliumkanal inhibitorer
BR0215405A (pt) Composições e processos de uso de collajolie
BR0014384A (pt) Compostos para o tratamento da isquémia
ATE293925T1 (de) Knochendistraktionsvorrichtung
TR200100410T2 (tr) 2-(purin-9-il)-tetrahidrofuran-3,4-diol türevleri.
CL2010000606A1 (es) Uso de derivados de eritropoyetina en la preparacion de un medicamento util para proteger, mantener, mejorar o recuperar la viabilidad de celulas que responden a eritropoyetina en condiciones anomalas que afectan las celulas, tejidos u organos asociados; derivados de eritropoyetinas y composicion que las comprende (divisional de la solicitud 3188-2001).
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BR0316776A (pt) Formula para anti-infeccioso tópico
PT83933B (pt) Processo para a preparacao de composicoes estaveis de activador do plasminogenio humano, tipo tecido
BR9910573A (pt) Compostos antipicornavirais, preparação e uso dos mesmos
EA200300450A1 (ru) Фармацевтические растворы соединений модафинила
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
IL188092A0 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
NO20005332D0 (no) Forkjølelsesmiddel med isomalt som virksom bestanddel
MX9100441A (es) Procedimiento para fabricar preparados solidos orales,que contienen ifosfamida como agente activo
IT8320600A0 (it) Composizione per un'applicazione topica contenente, come sostanza attiva sull'elasticia', la morbidezza della pelle tiamorfolinone oppure uno dei suoi derivati.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements